Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

Related Citations for PubMed (Select 18754003)

1.

Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence.

Schwartz JB.

Clin Pharmacol Ther. 2009 Feb;85(2):198-203. doi: 10.1038/clpt.2008.165. Epub 2008 Aug 27.

PMID:
18754003
2.

Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.

Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J; CAP Investigators.

Clin Ther. 2008 Dec;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023.

PMID:
19167589
3.

Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.

Harikrishnan S, Rajeev E, Tharakan JA, Titus T, Ajit Kumar VK, Sivasankaran S, Krishnamoorthy KM, Nair K.

Indian Heart J. 2008 May-Jun;60(3):215-22.

PMID:
19240310
4.

Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease.

Pérez-Castrillón JL, Vega G, Abad L, Sanz A, Chaves J, Hernandez G, Dueñas A.

Am J Cardiol. 2007 Apr 1;99(7):903-5. Epub 2007 Feb 8.

PMID:
17398180
5.

The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.

Keleş T, Akar Bayram N, Kayhan T, Canbay A, Sahin D, Durmaz T, Ozdemir O, Aydoğdu S, Diker E.

Anadolu Kardiyol Derg. 2008 Dec;8(6):407-12.

6.

Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.

Goldberg AC, Bays HE, Ballantyne CM, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.

Am J Cardiol. 2009 Feb 15;103(4):515-22. doi: 10.1016/j.amjcard.2008.10.025. Epub 2008 Dec 26.

PMID:
19195513
7.

Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.

Backman JT, Luurila H, Neuvonen M, Neuvonen PJ.

Clin Pharmacol Ther. 2005 Aug;78(2):154-67.

PMID:
16084850
8.

Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease.

Leiter LA, Bays H, Conard S, Bird S, Rubino J, Hanson ME, Tomassini JE, Tershakovec AM.

Am J Cardiol. 2008 Dec 1;102(11):1495-501. doi: 10.1016/j.amjcard.2008.09.076. Epub 2008 Oct 23.

PMID:
19026303
9.

Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).

Alrasadi K, Awan Z, Alwaili K, Ruel I, Hafiane A, Krimbou L, Genest J.

Am J Cardiol. 2008 Nov 15;102(10):1341-7. doi: 10.1016/j.amjcard.2008.07.010. Epub 2008 Sep 11.

PMID:
18993152
10.

Beneficial effect of atorvastatin on erythropoietin responsiveness in maintenance haemodialysis patients.

Tsouchnikas I, Dounousi E, Papakonstantinou S, Ioannou K, Kelesidis A, Kotzadamis N, Xanthopoulou K, Tsakiris D.

Nephrology (Carlton). 2009 Sep;14(6):560-4. doi: 10.1111/j.1440-1797.2009.01084.x. Epub 2009 Mar 3.

PMID:
19422526
11.

Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.

Conard SE, Bays HE, Leiter LA, Bird SR, Rubino J, Lowe RS, Tomassini JE, Tershakovec AM.

Am J Cardiol. 2008 Dec 1;102(11):1489-94. doi: 10.1016/j.amjcard.2008.09.075. Epub 2008 Oct 23.

PMID:
19026302
12.

Statin effects on LDL and HDL cholesterol in South Asian and white populations.

Gupta M, Braga MF, Teoh H, Tsigoulis M, Verma S.

J Clin Pharmacol. 2009 Jul;49(7):831-7. doi: 10.1177/0091270009334376. Epub 2009 Apr 27.

PMID:
19398601
13.

Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.

Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP; ALLIANCE Investigators.

Am J Kidney Dis. 2009 May;53(5):741-50. doi: 10.1053/j.ajkd.2008.11.025. Epub 2009 Feb 11.

PMID:
19216014
15.
16.

Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.

Skalicka B, Kubanek M, Malek I, Vymetalova Y, Hoskova L, Podzimkova M, Kautzner J.

J Heart Lung Transplant. 2009 Jun;28(6):598-604. doi: 10.1016/j.healun.2009.03.014.

PMID:
19481021
17.

Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.

Balasubramanian R, Varadharajan S, Kathale A, Nagraj LM, Periyandavar I, Nayak UP, Sharma A, Bolmall C, Baliga VP.

J Indian Med Assoc. 2008 Jul;106(7):464-7.

PMID:
18975505
18.

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.

Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW 3rd, Sisk CM, Mitchel Y, Pasternak RC.

Am Heart J. 2009 Feb;157(2):352-360.e2. doi: 10.1016/j.ahj.2008.09.022. Epub 2008 Dec 20.

PMID:
19185645
19.

Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study.

Kawashiri MA, Nohara A, Tada H, Mori M, Tsuchida M, Katsuda S, Inazu A, Kobayashi J, Koizumi J, Mabuchi H, Yamagishi M.

Clin Pharmacol Ther. 2008 May;83(5):731-9. Epub 2007 Oct 24.

PMID:
17957184
20.

Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.

Meas T, Laloi-Michelin M, Virally M, Peynet J, Giraudeaux V, Kévorkian JP, Guillausseau PJ.

Eur J Intern Med. 2009 Mar;20(2):197-200. doi: 10.1016/j.ejim.2008.06.009. Epub 2008 Aug 15.

PMID:
19327612
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk